Related Experiment Video
Updated: Nov 16, 2025
10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
15.7K
Medication Management Performance in Parkinson's Disease: Examination of Process Errors
Catherine A Sumida1, Francesca V Lopez2, Emily J Van Etten3
1Department of Psychology, Washington State University, Pullman, WA 99164-4820, USA.
Summary
Parkinson's disease patients with mild cognitive impairment struggle with medication management, making more errors than those with normal cognition or healthy adults. This difficulty is linked to memory problems, suggesting a need for targeted support.
Area of Science:
- Neuroscience
- Gerontology
- Pharmacology
Background:
- Medication mismanagement is a significant risk for individuals with Parkinson's disease (PD), potentially worsening clinical outcomes.
- The specific types of medication errors (undertaking or overtaking) and their connection to cognitive status in PD remain unclear.
Purpose of the Study:
- To investigate medication management errors using the Medication Management Ability Assessment (MMAA) in Parkinson's disease patients with normal cognition (PD-NC) and mild cognitive impairment (PD-MCI).
- To compare MMAA performance between PD-NC, PD-MCI, and healthy adults (HA).
- To examine the relationship between cognitive function and medication management abilities in these groups.
Main Methods:
- A cohort of 74 healthy adults (HA), 102 PD-NC patients, and 45 PD-MCI patients were assessed.
- Participants completed the MMAA to evaluate undertaking, overtaking, and overall medication management errors.
- A comprehensive neuropsychological battery was administered to derive cognitive composite scores.
Main Results:
- PD-MCI patients demonstrated significantly worse overall performance on the MMAA and committed more undertaking and overall errors compared to HA and PD-NC groups.
- In the PD-MCI group, poorer MMAA performance correlated with deficits in delayed memory recall.
- No significant relationship between cognitive performance and MMAA errors was observed in the HA or PD-NC groups.
Conclusions:
- Parkinson's disease patients with mild cognitive impairment exhibit pronounced difficulties in medication management, especially in undertaking medications, compared to healthy adults and PD patients with normal cognition.
- Impaired delayed recall in PD-MCI is associated with poorer medication management, indicating a need for enhanced support for these individuals.
- Objective assessment of medication errors can aid clinicians in identifying PD patients who require adherence strategies and support.
Related Concept Videos
01:24Parkinson's Disease: Treatment
743
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
743
01:15Parkinson's Disease: Overview
1.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.2K
01:28Drug Therapy
153
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
153
01:15Drug Dosing: Geriatric Patients
102
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
102
01:25Peritoneal Dialysis III: Nursing Management
324
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
324
01:26Psychosis: Goals of Pharmacotherapy
315
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
315